Joanne Lee: Oh God, hit, appreciate the details. And then just given the differences and mechanism behind complement inhibition and retinal restoration how would you expect a one and done treatment like off operation could fit in with complement targeting drugs like and Bali and others? Would this be something patients could perhaps take and then afterwards at a follow up, receive complement inhibition to further prevent damage? Curious to see how you’d imagine OpRegen could be positioned in the treatment landscape?
Brian Culley: I imagine myself as a patient looking at two product profiles, one that requires a monthly or every other month injection in the eye. And I’m an elderly individual who has difficulty getting to a clinic six to 12 times a year and comparing that with a one time procedure approximately 30 minutes and I’m awake for it with multiple years, maybe a lifetime of benefit. So I think the product profile just screams preference, but I’m going to invite Dr. Hogue to add to my thoughts?
Gary Hogge: I, I think there’s two ways you can look at it. And both, both favor, hopefully patient outcome operation, potentially be used first and then follow up with the complement inhibitor. So you take care of an arrest, the GA you replaced with fresh RPE and you keep the foot receptors healthy and then given it is an aged dye, then the colan inhibition may further set up opportunity to succeed and, and be established for long-term benefit. Alternately, if you keep complement hip inhibition first, a decreased inflammatory cascade is ongoing put Ingen cells and they may be even more likely to succeed. But bottom line, the earlier intervention, the earlier identification of a much larger patient pool will help both patients, de physicians treat them.
Joanne. I’m going to actually combine your question a little bit with the question that we got from Kristen Kska from Cantor because one of the sort of fun ways I think about the complement inhibitor is that it’s sort of like one of those tower defense video games where it’s slowing a process. So you can imagine there will be more patients in the, the hot zone, the addressable zone that could be treated by us. So in terms of, of the utility OpRegen, if a complement inhibitor becomes established, I, I think again, you could see a greater number of patients that exist in that addressable patient population spectrum. Because some of the very early individuals with dry AMD who get onto complement inhibition, if in fact they are on for years and there’s 20% or so less progression, they might still be within an addressable profile for our product at some point in the future.
Operator: I would now like to turn the call over to Brian Culley for closing remarks.
Brian Culley: All right. Well thank you everyone. We absolutely and sincerely appreciate your support of Lineage as we look to position ourselves as a leader in cell therapy and cell transplant medicine. Thank you very much for joining the call today and have a great rest of your week.
Operator: Thank you ladies and gentlemen. This concludes today’s call. We thank you for your participation. You may now disconnect.